(Q43444286)

23 November 2017

title

Changes in serum albumin during treatment of chronic hepatitis B with lamivudine: effects of response and emergence of drug resistance (English)

1 reference

23 November 2017

1 reference

1 reference

Jason M Hui

1

1 reference

23 November 2017

Jacob George

2

1 reference

23 November 2017

Christopher Liddle

3

1 reference

23 November 2017

Rita Lin

4

1 reference

23 November 2017

Dev Samarasinghe

5

1 reference

23 November 2017

Evelyn Crewe

6

1 reference

23 November 2017

Geoffrey C Farrell

7

1 reference

23 November 2017

language of work or name

English

0 references

publication date

1 April 2002

1 reference

The American Journal of Gastroenterology

23 November 2017

published in

1 reference

23 November 2017

volume

97

1 reference

23 November 2017

issue

4

1 reference

23 November 2017

page(s)

1003-1009

1 reference

A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.

23 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2002.05621.X

Histological changes in liver biopsies after one year of lamivudine treatment in patients with chronic hepatitis B infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2002.05621.X

Prevalence of hepatitis C virus infection in patients with antiphospholipid syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2002.05621.X

Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Lamivudine Precore Mutant Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2002.05621.X

Lamivudine treatment in patients with severely decompensated cirrhosis due to replicating hepatitis B infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2002.05621.X

Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2002.05621.X

Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2002.05621.X

Evolution of hepatitis B virus polymerase gene mutations in hepatitis B e antigen-negative patients receiving lamivudine therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2002.05621.X

Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2002.05621.X

Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2002.05621.X

Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2002.05621.X

The sequential occurrence of viral mutations in a liver transplant recipient re-infected with hepatitis B: hepatitis B immune globulin escape, famciclovir non-response, followed by lamivudine resistance resulting in graft loss.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2002.05621.X

Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2002.05621.X

Lamivudine as initial treatment for chronic hepatitis B in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2002.05621.X

10.1111/J.1572-0241.2002.05621.X

21 January 2018

Identifiers

DOI

1 reference

23 November 2017

1 reference